Scholarlink

Aim and Background <p>To evaluate the risk factors of peripartum cardiomyopathy (PPCM) and to determine the maternal and fetal outcome in women who were diagnosed as PPCM. The determinants of mortality and role of bromocriptine in improving maternal outcome were also evaluated.</p> Methods <p>A detailed clinical history, obstetric and cardiac examination and all necessary investigation were done for all women who presented with signs of heart failure late in pregnancy or postpartum. Twenty-five women were diagnosed as PPCM and included in this study. The risk factors, maternal–fetal outcome, and follow-up at 6&#xa0;weeks were noted.</p> Result <p>The occurrence of PPCM in our institution was 1.37 per 1000 live birth. Mean age of the study population was 25.96 ± 4.2&#xa0;years. Sixty-four percentage were multigravida and 84% presented in antenatal period. The majority (56%) of women presented with NYHA grade IV. The mean NT-proBNP was 2718.96 ± 3882.52&#xa0;pg/ml. The mean LVEF was 30.2 ± 9.02%. Most common risk factor was preeclampsia (64%) followed by anemia (32%). Ninety-four percentage of women were discharged alive, 4% required readmission, and mortality rate was 8%. The mean LVEF was 46.36 ± 8.04% at 6-week follow-up, and 45% had full recovery. The mean improvement in LVEF was significantly higher in bromocriptine user group (<i>p</i> = 0.024).</p> Conclusion <p>Early echocardiography in the suspected patients helps in timely diagnosis and good outcome. Bromocriptine is a promising drug for improving maternal, but needs more robust data.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Maternal and Perinatal Outcome of Peripartum Cardiomyopathy: A Single-Center Study in a Tertiary Referral Unit of India

  • 期刊论文

  • 发表日期：

    2025年9月27日

查看全文
  • Suchandana Dasgupta,
  • Jyotsna Suri,
  • Rekha Bharti,
  • Sumitra Bachani,
  • Supriya Hazarika,
  • Himal Singla,
  • Sandeep Bansal

摘要

Aim and Background

To evaluate the risk factors of peripartum cardiomyopathy (PPCM) and to determine the maternal and fetal outcome in women who were diagnosed as PPCM. The determinants of mortality and role of bromocriptine in improving maternal outcome were also evaluated.

Methods

A detailed clinical history, obstetric and cardiac examination and all necessary investigation were done for all women who presented with signs of heart failure late in pregnancy or postpartum. Twenty-five women were diagnosed as PPCM and included in this study. The risk factors, maternal–fetal outcome, and follow-up at 6 weeks were noted.

Result

The occurrence of PPCM in our institution was 1.37 per 1000 live birth. Mean age of the study population was 25.96 ± 4.2 years. Sixty-four percentage were multigravida and 84% presented in antenatal period. The majority (56%) of women presented with NYHA grade IV. The mean NT-proBNP was 2718.96 ± 3882.52 pg/ml. The mean LVEF was 30.2 ± 9.02%. Most common risk factor was preeclampsia (64%) followed by anemia (32%). Ninety-four percentage of women were discharged alive, 4% required readmission, and mortality rate was 8%. The mean LVEF was 46.36 ± 8.04% at 6-week follow-up, and 45% had full recovery. The mean improvement in LVEF was significantly higher in bromocriptine user group (p = 0.024).

Conclusion

Early echocardiography in the suspected patients helps in timely diagnosis and good outcome. Bromocriptine is a promising drug for improving maternal, but needs more robust data.